Zobrazeno 91 - 100
of 192
pro vyhledávání: ''
Autor:
Jan Liliemark, Jonas Wallvik, Devinder Gill, Stephen P. Mulligan, Bertil Uggla, Gunnar Juliusson, Viggo Jønsson, Mark Hertzberg, J. E. Norman, Karin Karlsson, Mats Strömberg, Roger McLennan, Gunnel Sundström, Jens Hammerstrøm, Yvonne Brandberg, Hemming Johansson
Publikováno v:
Leukemialymphoma. 55(12)
We conducted a randomized phase III trial to compare the efficacy and safety of two purine analogs, cladribine and fludarabine, with high-dose chlorambucil, in patients with previously untreated chronic lymphocytic leukemia (CLL). Between 1997 and 20
Publikováno v:
Leukemialymphoma. 55(10)
Patients with relapsed/refractory (R/R) multiple myeloma (MM) complicated by severe heart failure typically do not tolerate conventional chemotherapy. Our previous study indicated that R/R MM patients with severe comorbidities could benefit from cont
Autor:
Arne Kolstad, Alexander Fosså, Marianne Brodtkorb Eide, Erlend B. Smeland, Grete F. Lauritzsen, Harald Holte, Knut Liestøl, Yngvild Nuvin Blaker
Publikováno v:
Leukemialymphoma. 55(10)
High dose chemotherapy with autologous stem cell transplant (HD-ASCT) is a recommended procedure for patients with transformed indolent B-cell lymphoma from the pre-rituximab era. In this retrospective single-center study, we present our experience w
Autor:
Eloy del Potro, Carlos Grande, German Hiv Lymphoma Cohort, Christoph Wyen, Ángeles Fidalgo Fernández, Heribert Knechten, Montserrat Perez, Nicola Gökbuget, Jan van Lunzen, Josep-Maria Ribera, Jan Thoden, Albert Oriol, Ferran Vall-Llovera, Olga García, Lourdes Escoda, Christian Hoffmann, Mireia Morgades, Salut Brunet, Dieter Hoelzer, Jordi Esteve, Markus Müller, Natalia Alonso, Blanca Xicoy, José González, Jan-Christian Wasmuth, Philipp Schommers, Christoph Mayr, Gerd Fätkenheuer, Marcus Hentrich
Publikováno v:
Leukemialymphoma. 55(10)
The results of intensive immunochemotherapy were analyzed in human immunodeficiency virus (HIV)-related Burkitt lymphoma/leukemia (BLL) in two cohorts (Spain and Germany). Alternating cycles of chemotherapy were administered, with dose reductions for
Autor:
Anne Lerberg Nielsen, Karen Juul Mylam, Francesco d'Amore, Peter de Nully Brown, Martin Hutchings, Tarec Christoffer El-Galaly, Martin Bøgsted, Annika Loft, Lars C. Gormsen, Peter Kamper, Hans Erik Johnsen, Anne Bukh, Victor Vishwanath Iyer
Publikováno v:
El-Galaly, T C, Hutchings, M, Mylam, K J, de Nully Brown, P, Bukh, A, Johnsen, H E, Kamper, P, Loft, A, Iyer, V, Gormsen, L C, Nielsen, A L, Bøgsted, M & d'Amore, F 2014, ' Impact of 18 F-fl uorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma : fewer cases with stage I disease and more with skeletal involvement ', Leukemia and Lymphoma, vol. 55, no. 10, pp. 2349-2355 . https://doi.org/10.3109/10428194.2013.875169
El-Galaly, T C, Hutchings, M, Juul Mylam, K, Brown, P D, Bukh, A, Johnsen, H E, Kamper, P, Loft, A, Iyer, V, Gormsen, L C, Nielsen, A L, Bogsted, M & d'Amore, F 2014, ' Impact of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma : Fewer cases with stage I disease and more with skeletal involvement ', Leukemia and Lymphoma, vol. 55, no. 10, pp. 2349-2355 . https://doi.org/10.3109/10428194.2013.875169
El-Galaly, T C, Hutchings, M, Juul Mylam, K, Brown, P D, Bukh, A, Johnsen, H E, Kamper, P, Loft, A, Iyer, V, Gormsen, L C, Nielsen, A L, Bogsted, M & d'Amore, F 2014, ' Impact of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma : Fewer cases with stage I disease and more with skeletal involvement ', Leukemia and Lymphoma, vol. 55, no. 10, pp. 2349-2355 . https://doi.org/10.3109/10428194.2013.875169
F-18-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is a highly accurate staging method in classical Hodgkin lymphoma (cHL). We retrospectively compared the staging results obtained in two large cohorts of patients with
Autor:
Brijesh Arora, Sumeet Gujral, Nehal Khanna, Venkatesh Rangarajan, Mary Ann Muckaden, Tanuja Shet, Deepak Kumar, Epari Sridhar, Hari Menon, Siddhartha Laskar, Shripad Banavali, Reena Nair, Manju Sengar
Publikováno v:
Leukemialymphoma. 55(10)
One hundred and fifty-one patients aged between 3 and 70 years with early stage unfavorable Hodgkin lymphoma were included. Patients received 4-6 cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) chemotherapy and involved field rad
Autor:
Kyung Un Choi, Nari Shin, Chang Hun Lee, Jung Hee Lee, Kyung Bin Kim, Jee Yeon Kim, Dong Hoon Shin, Hyun Jung Lee, Won Young Park, Mee Young Sol
Publikováno v:
Leukemialymphoma. 55(9)
Polycomb group (PcG) proteins are evolutionarily conserved regulators of gene expression that contribute to normal lymphocyte development, and are involved in malignant transformation of these cells. Recently, BMI1 and EZH2 have been shown to be invo
Autor:
David R. H. Christie, Mary Gospodarowicz, Marta Bruno-Ventre, Silvia Govi, Yeon Park, Barbara Pro, Nick Pavlakis, Emerenziana Marturano, John Radford, Andrés J.M. Ferreri, Carlo Messina, David Porter, Jayasingham Jayamohan, Elías A. Gracia Medina, Silvia Mappa, Emanuele Zucca, Dae Seog Heo
Publikováno v:
Leukemialymphoma. 55(8)
Indolent lymphomas primarily involving the skeleton (iPBL) represent1% of all primary bone lymphomas. The management and prognosis have not been previously described. Patients with primary and secondary iPBL were selected from an international databa
Autor:
Lotta Hansson, Stefan Norin, Sandra Eketorp Sylvan, Jeanette Lundin, Claes Karlsson, Anders Österborg
Publikováno v:
Leukemialymphoma. 55(8)
Patients with fludarabine-refractory (FR) chronic lymphocytic leukemia (CLL) receive novel agents in pivotal, non-randomised phase-2 trials. Understanding outcome of FR-CLL in health-care may provide important contextual information. Records from 130
Autor:
Françoise Berger, Evelyne Callet-Bauchu, Josette Brière, Alexandra Traverse-Glehen, Nicolas Munoz-Bongrand, Pauline Brice, Julien Lenglet, Nicolas Mounier, Claire Benet, Catherine Thieblemont, Lucile Baseggio, Catherine Traulle, Maria-Elena Noguera, Martine Ffrench, Gilles Salles, Pascale Felman, Sandy Amorin, Bertrand Coiffier
Publikováno v:
Leukemialymphoma. 55(8)
Splenectomy is considered as one of the first-line treatments for symptomatic patients with splenic marginal zone lymphoma (SMZL). Between 1997 and 2012, 100 hepatitis C virus-negative patients with SMZL were treated by splenectomy as first-line trea